Enlivex (ENLV) Non-Current Debt (2019 - 2023)
Enlivex (ENLV) posted quarterly Non-Current Debt of $7.2 million for Q2 2023, up 54.22% year-over-year from $4.6 million in Q2 2022, and up 70.7% quarter-over-quarter from $4.2 million in Q4 2022.
Enlivex (ENLV) Non-Current Debt (2019 - 2023) Analysis & Trends
Enlivex's Non-Current Debt history runs 5 years deep, the most recent figure standing at $7.2 million for Q2 2023.
- In Q2 2023, Non-Current Debt rose 54.22% year-over-year to $7.2 million; the TTM figure through Jun 2023 stood at $7.2 million (up 54.22% YoY), while the FY2022 annual figure was $4.2 million, down 22.17% from the prior year.
- Non-Current Debt for Q2 2023 stood at $7.2 million, up from $4.2 million in the prior quarter.
- The five-year high for Non-Current Debt was $7.2 million in Q2 2023, with the low at $298000.0 in Q4 2019.
- The 5-year median for Non-Current Debt is $4.2 million (2022), against an average of $3.2 million.
- Peak annual rise in Non-Current Debt reached 1046.17% in 2022, while the deepest fall reached 22.17% in 2022.
- Enlivex's Non-Current Debt stood at $298000.0 in 2019, then surged by 67.45% to $499000.0 in 2020, then soared by 979.96% to $5.4 million in 2021, then dropped by 22.17% to $4.2 million in 2022, then soared by 70.7% to $7.2 million in 2023.
- Business Quant data shows ENLV's Non-Current Debt at $7.2 million in Q2 2023, $4.2 million in Q4 2022, and $4.6 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 8.96 Bn |
| 10 | Enlivex | 4.50 Mn | -1.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 7.16 Mn |
| Dec 31, 2022 | 4.19 Mn |
| Jun 30, 2022 | 4.64 Mn |
| Dec 31, 2021 | 5.39 Mn |
| Jun 30, 2021 | 405,000.00 |
| Dec 31, 2020 | 499,000.00 |
| Dec 31, 2019 | 298,000.00 |